Selvita SA, of Krakow, Poland, said the first patient was dosed with SEL24 in a phase I/II trial for acute myeloid leukemia. SEL24 is a Selvita-developed first-in-class dual PIM/FLT3 kinase inhibitor with a unique activity profile in oral formulation, the company said.